Gene

NTRK1

neurotrophic receptor tyrosine kinase 1

Explore in graph →CI-GENE-00017359HGNC:8031 ENSG00000198400 NCBI 4914 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (101)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 51–100 of 101 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
NTRK1 G595R1
Selitrectinib	Solid NeoplasmCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	submitted

Cohorts

Alteration frequency by cohort (114)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

gdcObserved114 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Liver Hepatocellular Carcinoma TCGA-LIHC	Hepatocellular Carcinoma

Literature

Linked publications (38)

25 per page, newest first.

pubmedPublishedShowing 1–25 of 38 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
· Lancet Oncol · 2020 · PMID 31838007 · validated civic_curation pubmed
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
· N Engl J Med · 2018 · PMID 29466156 · validated civic_curation pubmed
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
· Lancet Oncol · 2018 · PMID 29606586 · validated civic_curation pubmed
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
· Cancer Discov · 2017 · PMID 28183697

NTRK1 G595R + NTRK1 G667S1
Larotrectinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Resistance	2	accepted	EID9593 A 29-year-old male with NTRK-fusion positive NSCLC demonstrated initial response to Larotrectinib but progressed after devloping solvent-front (TRKA G595R) and xDFG (TRKA G667S) mutations. PMID 30624546 · Hong et al., 2019 · Open in CIViC	civic

NTRK1 G595R + NTRK1 G667S1

Larotrectinib

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Resistance

accepted

EID9593

A 29-year-old male with NTRK-fusion positive NSCLC demonstrated initial response to Larotrectinib but progressed after devloping solvent-front (TRKA G595R) and xDFG (TRKA G667S) mutations.

PMID 30624546 · Hong et al., 2019 · Open in CIViC

NTRK1 Fusion2
Larotrectinib	Sarcoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID6102 One Patient with soft tissue sarcoma and a NTRK1-PDE4DIP fusion was treated with larotrectinib and exhibited a partial response. Treatment was done within a multicentre, open-label, phase 1/2 study an… (full text at CIViC) PMID 29606586 · Laetsch et al., 2018 · Open in CIViC	civic
〃	Sarcoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID7420 In a pediatric phase 1 trial (NCT02637687), a boy aged 15 months with soft tissue sarcoma of the right upper thigh harbored the PDE4DIP-NTRK1 fusion. After resection and the failure of initial chemoth… (full text at CIViC) PMID 30204247 · DuBois et al., 2018 · Open in CIViC	civic

NTRK1 Fusion2
(oncogenic)	Malignant Breast Neoplasm	Oncogenic	C	Supports Oncogenicity	2	accepted	EID10897 Of the 4854 Breast Cancer patients analyzed by Memorial Sloan Kettering-IMPACT targeted DNA sequencing and MSK-Fusion targeted RNA-seq, fusions were detected in 27 patients. One of these patients was … (full text at CIViC) PMID 32348852 · Ross et al., 2020 · Open in CIViC	civic
〃	Malignant Breast Neoplasm	Oncogenic	C	Supports Oncogenicity	2	accepted	EID10898 A breast cancer patient harbored the SCP2::NTRK1 fusion. This report demonstrated positive pan-tyrosine receptor kinase (TRK) immunohistochemical staining in a core-needle biopsy taken from the patien… (full text at CIViC) PMID 33002320 · Ruiz-Cordero et al., 2020 · Open in CIViC	civic

NTRK1 Fusion6
Entrectinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	accepted	EID1868 In 1378 cases of NSCLC screened for NTRK1 rearrangements, 2 were identified (frequency 0.1%). One patient with SQSTM1-NTRK1 was treated with entrectinib in a phase 1 study. The patient had resolution … (full text at CIViC) PMID 26565381 · Farago et al., 2015 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	accepted	EID2950 Two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the anti… (full text at CIViC) PMID 28183697 · Drilon et al., 2017 · Open in CIViC	civic
Larotrectinib	Infantile FibrosarcomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID6103 One patient with infantile fibrosarcoma and a NTRK1-SQSTM1 fusion was treated with larotrectinib and exhibited a partial response. Treatment was done within a multicentre, open-label, phase 1/2 study … (full text at CIViC) PMID 29606586 · Laetsch et al., 2018 · Open in CIViC	civic
〃	Infantile FibrosarcomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID8865 In a pediatric phase 1 trial (NCT02637687), a 2 year old with infantile fibrosarcoma of the shoulder harbored the SQSTM1-NTRK1 fusion. After two surgical resections and multiple rounds of chemotherapy… (full text at CIViC) PMID 30204247 · DuBois et al., 2018 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID11574 Drilon et al (2022) assessed the efficacy and safety of larotrectinib in lung cancer patients with TRK fusions in a phase II adult/young adult trial (NCT02576431) and a phase I adult trial (NCT0212291… (full text at CIViC) PMID 35085007 · Drilon et al., 2022 · Open in CIViC	civic
〃	Thyroid Gland Papillary CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID11575 Bragas et al (2022) report a case study of a 50-year old female with a papillary thyroid carcinoma with multiple metastases containing a SQSTM1::NTRK1 fusion treated with larotrectinib. SQSTM1::NTRK1 … (full text at CIViC) PMID 35118995 · Bargas et al., 2022 · Open in CIViC	civic

NTRK1 Fusion9
Entrectinib	Malignant Ovarian Neoplasm	Predictive	C	Does Not Support Resistance	2	submitted	EID11743 56-year-old women was diagnosed with a stage IV ovarian cancer. Debulking surgery, and chemotherapy was given for 10 months. However, disease recurred and at this time NGS was performed which detected… (full text at CIViC) PMID 35251641 · Endo et al., 2022 · Open in CIViC	civic
〃	Myofibroma	Predictive	C	Supports Sensitivity Response	1	accepted	EID11861 In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included a patient with infantile… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC	civic
〃	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID10094 BaF3 cells transduced with a number of NTRK fusions demonstrated sensitivity to entrectinib. IC50 values were measured from cell viability assays (Cell Titer Glo) following 72-hour incubation with ent… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic
Larotrectinib	Sarcoma	Predictive	C	Supports Sensitivity Response	4	accepted	EID6101 Four patients with infantile fibrosarcoma and soft tissue sarcoma and a TPM3::NTRK1 fusion were treated with larotrectinib. All four patients had a partial or complete response in the target lesion. T… (full text at CIViC) PMID 29606586 · Laetsch et al., 2018 · Open in CIViC	civic
〃	Spindle Cell Sarcoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID7419 In a pediatric phase 1 trial (NCT02637687), a 12-year-old boy with TPM3-NTRK1 fusion was treated with Larotrectinib as first line treatment as no standard treatment options were available. Following a… (full text at CIViC) PMID 30204247 · DuBois et al., 2018 · Open in CIViC	civic
〃	Thyroid Gland Papillary CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID8042 A healthy 12 year old with right neck mass was found to have heterogeneous solid mass originating from the right thyroid lobe. Total thyroidectomy confirmed papillary thyroid carcinoma (PTC) with mult… (full text at CIViC) PMID 29610391 · Ronsley et al., 2018 · Open in CIViC	civic
〃	Lung Carcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID11692 The goal of this study was to assess the efficacy and safety of larotrectinib in patients with TRK fusion–positive lung cancers. This was achieved by reviewing data from two global, multicenter clinic… (full text at CIViC) PMID 35085007 · Drilon et al., 2022 · Open in CIViC	civic
Larotrectinib + LestaurtinibSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	accepted	EID978 NTRK1 fusions (one LMNA-NTRK1 and two TPM3-NTRK1) were identified in 2% of Korean colorectal cancer patients (147 patients). TrkA (NTRK1) protein expression was associated with presence of NTRK1 gene … (full text at CIViC) PMID 26716414 · Park et al., 2016 · Open in CIViC	civic
Larotrectinib Regimen	Solid NeoplasmCURATED_BROADER	Predictive	A	Supports Sensitivity Response	5	accepted	EID11703 This was a Phase 1/2 study in which 55 patients between 4 months and 76 years of age with TRK-fusion positive tumors were given NTRK inhibitor Larotrectinib. Patients had 17 unique NTRK fusion type… (full text at CIViC) PMID 29466156 · Drilon et al., 2018 · Open in CIViC	civic

NTRK1 Fusion9
(oncogenic)	NTRK-Rearranged Spindle Cell NeoplasmALIAS	Oncogenic	C	Supports Oncogenicity	1	accepted	EID11704 An intra-chromosomal TPR::NTRK1 fusion was found in a superficial soft tissue tumor located on the hand of a 7-year-old girl. The tumor had a prominently infiltrative growth pattern reminiscent of lip… (full text at CIViC) PMID 27259011 · Agaram et al., 2016 · Open in CIViC	civic
〃	Malignant NeoplasmALIAS	Oncogenic	C	Supports Oncogenicity	1	accepted	EID11705 A male child (1 year old) presented with a rapidly growing tumor in the cervical region that had been present for 2 months. It was a firm to hard soft-tissue mass. Radiologic imaging disclosed a tumor… (full text at CIViC) PMID 32489127 · Rekhi et al., 2021 · Open in CIViC	civic
Entrectinib	High-Grade Glioma, NOS	Predictive	C	Supports Sensitivity Response	3	accepted	EID11851 In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included one patient (4 yo) with … (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC	civic
Larotrectinib	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Sensitivity Response	4	accepted	EID11706 A female patient, 43 presented with right lower quadrant pain, and was surgically treated for perforated appendicitis including segmental small-bowel resection. Invasive adenocarcinoma stage IIB (pT4a… (full text at CIViC) PMID 35815302 · Kasi et al., 2022 · Open in CIViC	civic
〃	Gliosarcoma	Predictive	C	Supports Sensitivity Response	4	accepted	EID11746 A 9-month-old boy with no family history of cancer presented with increased head circumference, and MRI demonstrated a solid lesion in the left frontal lobe. A subtotal surgical resection was performe… (full text at CIViC) PMID 35034013 · Mançano et al., 2022 · Open in CIViC	civic
〃	Malignant Thyroid Gland Neoplasm	Predictive	C	Supports Sensitivity Response	4	accepted	EID11748 A 4.3-year-old girl had I-131–refractory papillary thyroid carcinoma (PTC). There was lymph node involvement and lung metastases. She underwent thyroidectomy and neck dissection, and administration of… (full text at CIViC) PMID 34237031 · Lee et al., 2021 · Open in CIViC	civic
〃	Solid NeoplasmCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	accepted	EID9589 This Phase I study (NCT02122913) enrolled 70 heavily pretreated adult patients (median age 59.5 years) with various advanced solid tumors. Among them, one patient was identified with a TPR::NTRK1 fusi… (full text at CIViC) PMID 30624546 · Hong et al., 2019 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	accepted	EID11744 In the clinical trial NCT01775072, one patient had TPR::NTRK1 positive non-small cell lung cancer, and had a partial response with larotrectinib treatment before eventual progression. PMID 33004339 · Cocco et al., 2021 · Open in CIViC	civic
〃	Thyroid Gland Papillary CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID11747 FFPE samples from 351 primary thyroid carcinomas were subjected to targeted gene rearrangement next-generation sequencing, and 11 NTRK rearrangements were found, all with intact kinase domains, and in… (full text at CIViC) PMID 32457407 · Chu et al., 2020 · Open in CIViC	civic

NTRK1 Fusion12
(diagnostic)	NTRK-Rearranged Spindle Cell NeoplasmALIAS	Diagnostic	B	Supports Positive	3	accepted	EID7293 Among pediatric fibroblastic and myofibroblastic proliferating superficial lesions, lipofibromatosis (LPF), composed of an admixture of adipose tissue and fibroblastic elements, has been variously cla… (full text at CIViC) PMID 27259011 · Agaram et al., 2016 · Open in CIViC	civic
Entrectinib	Solid NeoplasmCURATED_BROADER	Predictive	A	Supports Sensitivity Response	5	accepted	EID11124 Describes a meta-analysis of three separate phase I or II trials: ALKA-372-001, STARTRK-1, and STARTRK-2. All of these evaluate entrectinib in NTRK fusion-positive solid tumours. 31/54 had objective r… (full text at CIViC) PMID 31838007 · Doebele et al., 2020 · Open in CIViC	civic
〃	Solid NeoplasmCURATED_BROADER	Predictive	A	Supports Sensitivity Response	3	accepted	EID2948 The overall safety and antitumor activity of entrectinib was described for two phase I trials of patients with advanced solid tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions. NTRK1 fusions were … (full text at CIViC) PMID 28183697 · Drilon et al., 2017 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	rejected	EID2947 1378 cases of NSCLC were screened. One patient (frequency 0.1%) with a NTRK1 gene rearrangement (SQSTM1-NTRK1 Fusion) was treated with entrectinib in a phase 1 study. The patient had resolution of pri… (full text at CIViC) PMID 26565381 · Farago et al., 2015 · Open in CIViC	civic
Larotrectinib	Solid NeoplasmCURATED_BROADER	Predictive	A	Supports Sensitivity Response	4	accepted	EID6567 This was a Phase 1/2 study of 55 patients from 4 months to 76 years old with TRK-fusion positive tumors given NTRK inhibitor Larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall re… (full text at CIViC) PMID 29466156 · Drilon et al., 2018 · Open in CIViC	civic
〃	Sarcoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID6569 In a Phase 1/2 study involving 15 pediatric patients with infantile fibrosarcoma or soft tissue sarcoma, 8 patients had NTRK1 fusions. The patients were administered Larotrectinib, and 7 out of 8 pati… (full text at CIViC) PMID 29606586 · Laetsch et al., 2018 · Open in CIViC	civic
〃	Malignant Pancreatic Neoplasm	Predictive	C	Supports Sensitivity Response	3	submitted	EID7649 A patient with pancreatic cancer harboring NTRK fusion was treated with larotrectinib. The best overall response was PR at 2 months but the tumor progressed after 6 months. PMID 31605106 · O'Reilly et al., 2019 · Open in CIViC	civic
〃	Malignant NeoplasmALIAS	Predictive	C	Supports Sensitivity Response	2	accepted	EID2953 Results from a phase I study show that the TRK inhibitor LOXO-101 is well tolerated and effective, with patients whose tumors bear NTRK fusions responding well and durably to this targeted therapy. Th… (full text at CIViC) PMID 26603524 · 2016 · Open in CIViC	civic
〃	Sarcoma	Predictive	C	Supports Sensitivity Response	2	rejected	EID2956 LOXO-101 is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors. The tumor of a 41-year-old woman with soft-tissue sarcoma metastatic to the… (full text at CIViC) PMID 26216294 · Doebele et al., 2015 · Open in CIViC	civic
〃	Malignant Pancreatic Neoplasm	Predictive	C	Supports Sensitivity Response	2	submitted	EID6051 In a Phase I/II study of Larotrectinib, highly selective TRK inhibitor, one patient with pancreatic cancer with NTRK fusion showed PR. PMID 29466156 · Drilon et al., 2018 · Open in CIViC	civic
〃	Cholangiocarcinoma	Predictive	C	Supports Sensitivity Response	2	submitted	EID6052 In a Phase I/II study of Larotrectinib, highly selective TRK inhibitor, two patient with cholangiocarcinoma with NTRK fusion was enrolled. One of the two patient showed PR. PMID 29466156 · Drilon et al., 2018 · Open in CIViC	civic
Crizotinib + Larotrectinib + LestaurtinibSubstitutes	Lung Adenocarcinoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID1019 Two patients were found to harbor gene fusions maintaining the kinase domain of NTRK1 (3' partner), specifically: MPRIP-NTRK1 and CD74-NTRK1. Both of these fusions lead to constitutive kinase activit… (full text at CIViC) PMID 24162815 · Vaishnavi et al., 2013 · Open in CIViC	civic